Results from previous and the present studies reflect that patients with HR-negative, HER2-positive breast cancer are more likely to achieve pCR with chemotherapy plus dual HER2-blockade than those with HR-positive, HER2-positive breast cancer. Here, ERBB2 is linked to breast carcinoma.